Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population.

Autor: Marruecos-Querol J; Radiation Oncology Department, Catalan Institute of Oncology, ICO Girona, Girona, Spain. jmarruecos@iconcologia.net., Rubió-Casadevall J; Medical Oncology Department, Catalan Institute of Oncology, Girona, Spain., Lozano A; Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Buxó M; Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Puigdemont M; Epidemiology Unit and Girona Cancer Registry, Descriptive Epidemiology, Genetics and Cancer Prevention Group, IDIBGI, Catalan Institute of Oncology, Girona, Spain., Linares I; Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Planas I; Radiation Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Vayreda J; Radiation Oncology Department, Catalan Institute of Oncology, ICO Girona, Girona, Spain., Cirauqui B; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Taberna M; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Quiroga V; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Tobed M; Otorhinolaryngology Department, Dr. Trueta Hospital, Girona, Spain., Borés A; Otorhinolaryngology Department, Dr. Trueta Hospital, Girona, Spain., Recalde S; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Saigi M; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Felip E; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Eraso A; Radiation Oncology Department, Catalan Institute of Oncology, ICO Girona, Girona, Spain., Mesía R; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Aug; Vol. 25 (8), pp. 2384-2392. Date of Electronic Publication: 2023 Mar 21.

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study

Autor: Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio-RT) with Pb may be an alternative for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1d9125ed82c20f67ebaaf32b3723807d
https://pubmed.ncbi.nlm.nih.gov/33876416

Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).

Autor: Humbert-Vidan L; Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Sciences, Comprehensive Cancer Centre, King's College London, London, UK. Electronic address: laia.humbert-vidan@kcl.ac.uk., Hansen CR; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Fuller CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Centre, Houston, TX, United States., Petit S; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., van der Schaaf A; Department of Radiation Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands., van Dijk LV; Department of Radiation Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands., Verduijn GM; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Langendijk H; Department of Radiation Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands., Muñoz-Montplet C; Department of Medical Physics and Radiation Protection, Catalan Institute of Oncology, Girona, Spain; Department of Medical Sciences, University of Girona, Girona, Spain., Heemsbergen W; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Witjes M; Department of Radiation Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands., Mohamed ASR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Centre, Houston, TX, United States., Khan AA; Department of Oral and Maxillofacial Surgery, Odense University Hospital, Odense, Denmark., Marruecos Querol J; Department of Medical Sciences, University of Girona, Girona, Spain; Department of Radiation Oncology, Catalan Institute of Oncology, Girona, Spain., Oliveras Cancio I; Department of Radiation Oncology, Catalan Institute of Oncology, Girona, Spain., Patel V; Department of Oral Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK., King AP; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK., Johansen J; Department of Oncology, Odense University Hospital, Odense, Denmark., Guerrero Urbano T; Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2022 Nov; Vol. 176, pp. 99-100. Date of Electronic Publication: 2022 Sep 28.

Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.

Autor: Biete Solà, A., Marruecos Querol, J., Calvo Manuel, F., Verger Fransoy, E., Rovirosa Casino, À., Grau de Castro, J., Heras González, M., Ramos Aguerri, A., Palacios Eito, A., Veiras Candal, C., Solano López, Mª.

Publikováno v: Clinical & Translational Oncology; Apr2007, Vol. 9 Issue 4, p244-250, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.